Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin–angiotensin–aldosterone system

Abstract

SPR has a greater antihypertensive effect than dual blockade of the RAAS in resistant hypertension. SPR at daily doses of 25-50 mg shows a potent antihypertensive effect when added to prior regimes of single RAAS axis blockade in patients with resistant arterial hypertension.